Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Sep;85(3):306-317.
doi: 10.1016/j.jinf.2022.06.009. Epub 2022 Jun 16.

Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults

Rajeka Lazarus  1 , Christian Taucher  2 , Claire Brown  3 , Irena Čorbic Ramljak  4 , Leon Danon  5 , Katrin Dubischar  4 , Christopher J A Duncan  6 , Susanne Eder-Lingelbach  4 , Saul N Faust  7 , Christopher Green  3 , Karishma Gokani  3 , Romana Hochreiter  4 , Johanna Kellett Wright  1 , Dowan Kwon  1 , Alexander Middleditch  1 , Alasdair P S Munro  7 , Kush Naker  3 , Florentina Penciu  1 , David Price  6 , Benedicte Querton  4 , Tawassal Riaz  1 , Amy Ross-Russell  7 , Amada Sanchez-Gonzalez  6 , Hayley Wardle  6 , Sarah Warren  7 , Adam Finn  8 ; Valneva Phase 1 Trial Group
Affiliations
Clinical Trial

Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults

Rajeka Lazarus et al. J Infect. 2022 Sep.

Abstract

Objectives: We aimed to evaluate the safety and optimal dose of a novel inactivated whole-virus adjuvanted vaccine against SARS-CoV-2: VLA2001.

Methods: We conducted an open-label, dose-escalation study followed by a double-blind randomized trial using low, medium and high doses of VLA2001 (1:1:1). The primary safety outcome was the frequency and severity of solicited local and systemic reactions within 7 days after vaccination. The primary immunogenicity outcome was the geometric mean titre (GMT) of neutralizing antibodies against SARS-CoV-2 two weeks after the second vaccination. The study is registered as NCT04671017.

Results: Between December 16, 2020, and June 3, 2021, 153 healthy adults aged 18-55 years were recruited in the UK. Overall, 81.7% of the participants reported a solicited AE, with injection site tenderness (58.2%) and headache (46.4%) being the most frequent. Only 2 participants reported a severe solicited event. Up to day 106, 131 (85.6%) participants had reported any AE. All observed incidents were transient and non-life threatening in nature. Immunogenicity measured at 2 weeks after completion of the two-dose priming schedule, showed significantly higher GMTs of SARS-CoV-2 neutralizing antibody titres in the highest dose group (GMT 545.6; 95% CI: 428.1, 695.4) which were similar to a panel of convalescent sera (GMT 526.9; 95% CI: 336.5, 825.1). Seroconversion rates of neutralizing antibodies were also significantly higher in the high-dose group (>90%) compared to the other dose groups. In the high dose group, antigen-specific IFN-γ expressing T-cells reactive against the S, M and N proteins were observed in 76, 36 and 49%, respectively.

Conclusions: VLA2001 was well tolerated in all tested dose groups, and no safety signal of concern was identified. The highest dose group showed statistically significantly stronger immunogenicity with similar tolerability and safety, and was selected for phase 3 clinical development.

Keywords: Adjuvanted vaccine; COVID-19; Coronavirus; CpG 1018; Inactivated vaccine; Neutralizing antibody; RBD-binding IgG antibody; S protein binding IgG antibody; SARS-CoV-2; Whole-virus vaccine.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest AF is a member of the Joint Committee on Vaccination and immunization and chair of the WHO European Technical Advisory Group of Experts on immunization. He is an investigator or provides consultative advice on clinical trials and studies of COVID-19 vaccines produced by AstraZeneca, Janssen, Valneva, Pfizer, and Sanofi, and of other vaccines from these and other manufacturers, including GlaxoSmithKline, VPI Pharmaceuticals, Takeda, and Bionet Asia. He receives no personal remuneration or benefits for any of this work. CTA, KD, SEL, RH, IC, BQ, and JCJ are employees of Valneva Austria GmbH.

Figures

Fig 1
Fig. 1
CONSORT Flow Chart VLA2001 Phase 1/2 trial.
Fig 2
Fig. 2
Plot of SARS-CoV-2 Neutralizing Antibodies (ND50) Over Time by Dose Groups (Days 1, 8, 22, 36, and 106).
Fig 3
Fig. 3
Plot of S-protein Specific IgG Antibody Titres (ELISA) Over Time by Dose Groups at Days 1, 8, 22, 36, and 106 (Per Protocol population).
Fig 4
Fig. 4
Correlation between neutralizing and IgG Antibody titers.
Fig 5
Fig. 5
Cellular Immune Response (Interferon Gamma).
See this image and copyright information in PMC

References

    1. Liu Q., Qin C., Liu M., Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect Dis Poverty. 2021;10 doi: 10.1186/S40249-021-00915-3. - DOI - PMC - PubMed
    1. Hall V., Hopkins S. C.OV-BOOST: evidence to support rapid booster deployment. Lancet. 2021;398:2209–2211. - PMC - PubMed
    1. Mathieu E., Ritchie H., Ortiz-Ospina E., Roser M., Hasell J., Appel C., Giattino C., Rodés-Guirao L. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021;5(7):947–953. doi: 10.1038/s41562-021-01122-8. . Epub 2021 May 10. Erratum in: Nat Hum Behav. 2021 Jun 17: PMID: 33972767. - DOI - PubMed
    1. World Health Organization . World Health Organization; 2021. Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19; pp. 1–30.
    1. Stefanelli P., Faggioni G., Lo Presti A., et al. Whole genome and phylogenetic analysis of two SARSCoV-2 strains isolated in Italy in January and February 2020: additional clues on multiple introductions and further circulation in Europe. Eurosurveillance. 2020;25:1–5. - PMC - PubMed

Publication types

Associated data